Leukeran Tablets (Chlorambucil)

Adult dose

1. Hodgkin's disease For monotherapy, administer chlorambucil orally at a dose of 0.2 mg/kg of body weight daily for 4～8 weeks. It is usually administered as part of combination therapy. 2. Certain types of non-Hodgkin lymphoma For monotherapy, the initial dose is 0.1～0.2 mg/kg of body weight daily for 4～8 weeks. For maintenance therapy, reduce the daily dose or administer intermittently. 3. Chronic lymphocytic leukemia Treatment with this medicine should be started after symptoms have progressed or when evidence of bone marrow failure is indicated by the peripheral blood cell count. Start treatment with 0.15 mg/kg of body weight daily until the total white blood cell count decreases to 10,000/㎣. After the first course is completed, restart treatment after 4 weeks and continue at 0.1 mg/kg of body weight daily. In patients with bone marrow failure, first treat with prednisolone and begin treatment with this medicine after bone marrow recovery is confirmed. 4. Waldenstrom's macroglobulinemia As an initial dose, administer 6～12 mg daily until leukopenia occurs, then reduce the dose to 2～8 mg daily.

Child dose

Used to treat Hodgkin's disease and non-Hodgkin lymphoma; the dosage is similar to that for adults.

This drug is a potent cytotoxic agent, so it should be used under the guidance of a physician experienced in such treatments. This drug can damage the bone marrow, reducing blood cell counts; therefore, blood tests should be frequently performed to monitor blood cell levels. This drug should not be used in patients who have developed resistance to it or have allergies to its components, or those who have recently received radiation therapy or other cytotoxic medications. Additionally, this drug should not be administered to patients with genetic lactose metabolism disorders. Patients with weakened bone marrow function or impaired kidney function should adjust the dose and closely monitor blood levels when using this drug. Patients with poor liver function should carefully monitor for hepatic toxicity symptoms and reduce the dose if necessary. Children with nephrotic syndrome or patients receiving high doses intermittently, as well as those with a history of seizures, should be closely monitored for an increased risk of seizures after using this drug. This drug can decrease the number of white blood cells, platelets, and red blood cells, and can cause various side effects such as gastrointestinal disturbances, liver dysfunction, and skin rashes. Severe skin reactions, pulmonary disease, seizures, and neurological abnormalities may rarely occur; if any unusual symptoms appear, consult health care professionals immediately. Long-term use of this drug may increase the risk of acute hematologic malignancies, so treatment effectiveness and risks should be carefully weighed before deciding on its use. During pregnancy, there is a risk of fetal malformations; therefore, administration should be avoided whenever possible, and both women and men on or planning to take this drug should ensure adequate contraception. In nursing mothers, it is safe to discontinue breastfeeding if this drug is being taken. In case of overdose, there may be a rapid decrease in blood cell counts and neurological symptoms; as there is no specific antidote, careful monitoring of blood status and necessary treatments should be conducted. This drug should be kept out of the reach of children, and transferring it to other containers should be avoided to prevent quality deterioration or accidents.

• Leukopenia
• neutropenia
• thrombocytopenia
• pancytopenia
• bone marrow suppression
• anemia
• irreversible bone marrow failure
• nausea
• vomiting
• diarrhea

This drug may be sensitive to air and moisture; therefore, it must be stored in a tightly sealed container. Additionally, it is essential to keep it in a cool, dry place in the refrigerator at a temperature between 2°C and 8°C to preserve its efficacy.

Appearance

Brown, biconvex, round film-coated tablet

Package unit

25 tablets/bottle